MET and liver cancer: The mRNA expression levels of MACC1 and c-Met in HepG2 liver cancer cells treated with different doses of SS-b2 (40 or 80 mg/L) for 24 h were significantly decreased relative to the control group (p < 0.05 and p < 0.01, respectively) (Figures 4(a) and 4(b)).